3 August 2020
Amsterdam, NL – A review of currently registered clinical trials of agents targeting Parkinson's disease (PD) reveals that there is a broad pipeline of both symptomatic and potentially disease-modifying therapies currently being evaluated. Investigators report that the outlook for patients is encouraging, given the wide range of therapeutics being clinically tested. They emphasize the importance of engaging the Parkinson's community in the research. Their analysis and results are published in the Journal of Parkinson's Disease.
PD is a neurodegenerative condition for which there is currently no cure. The incidence of PD is increasing, with the number of cases expected to double worldwide by 2040. The majority of current pharmacological treatments for PD were approved for clinical use in the second half of the last century, and they only provide symptomatic relief. Derivatives of these therapies continue to be explored in clinical trials, together with potentially disease-modifying therapies that may slow, stop, or reverse the condition.
“With the discovery of the first genetic risk factors for PD at the turn of this century, researchers have begun to develop a better understanding of the possible biological pathways that may be governing/influencing the progressive neurodegeneration associated with PD,” explained senior author Simon Stott, PhD, Deputy Director of Research, The Cure Parkinson’s Trust, London, UK. “These discoveries have led to a growing number of clinical trials targeting an increasing number of potentially disease-relevant mechanisms of action. It is important for the research and Parkinson’s communities to stay abreast of the extensive, ever-changing landscape in order to highlight trends and better manage expectations.”
This analysis provides the first broad overview of currently registered clinical trials of agents targeting PD. It demonstrates that there is currently a tremendous amount of clinical research being conducted on therapeutic agents for PD that is exploring a wide range of agents that have different mechanisms of action and therapeutic targets.
“The outlook is encouraging for the clinical trial field, given the broad range of therapeutics being clinically evaluated,” commented Richard Wyse, MD, Director of Research and Development, The Cure Parkinson’s Trust, London, UK. “Development of Parkinson’s biomarkers and new approaches to trial design, along with increasing levels of open data/open science and publishing of results for all trials will help hasten progress in bringing new Parkinson’s treatments forward.”
The investigators conducted a review of clinical trials of drug therapies for PD using trial data obtained from the ClinicalTrials.gov international database and performed a breakdown analysis of studies that were active as of January 21, 2020. They identified 145 registered and ongoing clinical trials for therapeutics targeting PD, of which 51 (35%) are Phase 1, 66 (46%) are Phase 2, and 28 (19%) are Phase 3. There are 57 trials (39%) focusing on long-term disease modifying therapies, with the remaining 88 trials (61%) investigating therapies for short-term, daily symptomatic relief. A total of 50 (34%) trials are testing repurposed therapies.
Caption: Agents in active PD drug trials, as of January 21, 2020 on ClinicalTrials.gov (by phase, DMT/ST and therapy category)
Parkinson's research advocates were the driving force behind this study.
As co-author Susan Buff, a Parkinson's care partner, research advocate, and publisher of PDTrialTracker.info, noted, “The patient community brings a combination of the lived experience of the disease, a sense of urgency, and an array of career backgrounds and skill sets that can all contribute immensely to the research process. Hopefully, having a clearer view of the trial pipeline will enable greater awareness around opportunities for researcher/patient collaboration."
Co-author Kevin McFarthing, PhD, a patient advocate and expert in innovation management who maintains The Hope List (bit.ly/ParkinsonsHopeList) and contributes to the Journal of Parkinson’s Disease Clinical Trials Highlights section, added, “As patients and carers, we have a vested interest in the success of clinical trials, and we hope that a greater awareness of the pipeline will increase the chances of more therapies reaching patients in the near future. The number of clinical trials under way is encouraging for the Parkinson’s community, especially the high proportion of repurposed initiatives that increase the chances of a new therapy becoming available more quickly. The breadth of targets for both symptomatic and disease-modifying therapies shows the value of primary research over many years.
Gary Rafaloff, PhD, a patient advocate and co-author of this study, has been involved in Parkinson’s research since his diagnosis eight years ago, initially as a trial volunteer and more recently as a member of a research study team. “My hope is that this research review will make it easier for those who conduct research, those who fund research, and most importantly, those who volunteer to participate in research, to collaborate more efficiently with the ultimate goal of discovering more effective therapies, and possibly a cure, for the disease," he said.
“It is important not only for the research community to be aware of this clinical trial landscape, but also for the Parkinson's patient community from whom the pool of brave volunteers to participate in the trials is gathered. It is extremely important for the patient and carer community to become more engaged with the research, providing valuable insights into how different aspects of the clinical trial process could potentially be improved,” concluded Dr. Stott.
NOTES FOR EDITORS
Full open access study: "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020" by Kevin McFarthing, Susan Buff, Gary Rafaloff, Thea Dominey, Richard K. Wyse, and Simon R.W. Stott (doi.org/10.3233/JPD-202128) published in the Journal of Parkinson's Disease in Volume 10, Issue 3 (August 2020) by IOS Press. This article is openly available at: content.iospress.com/articles/journal-of-parkinsons-disease/jpd202128.
To request the full text of the study or additional information contact Diana Murray, IOS Press (+1 718-640-5678 or email@example.com). Journalists wishing to interview the study's authors should contact Simon Stott (firstname.lastname@example.org).
About the Journal of Parkinson's Disease
Celebrating its 10th anniversary in 2020, the Journal of Parkinson's Disease (JPD) is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Parkinson’s disease. The journal is international and multidisciplinary and aims to promote progress in the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis and treatment of Parkinson’s disease. It publishes research reports, reviews, short communications, and letters-to-the-editor and offers very rapid publication and an affordable open access option. JPD has a Journal Impact Factor of 5.178 according to Journal Citation Reports (Clarivate, 2020) and is published by IOS Press. journalofparkinsonsdisease.com
About IOS Press
IOS Press is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes more than 80 international peer-reviewed journals and about 75 book titles each year on subjects ranging from computer science, artificial intelligence, and engineering to medicine, neuroscience, and cancer research. iospress.com